Hazlett, Burt & Watson’s AstraZeneca AZN Stock Holding History

Hazlett, Burt & Watson’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	1,107 +28	+3%	+$5.27K	0.06%	259
2026 Q1	$212K	Buy	1,079 +129	+14%	+$24.9K	0.07%	240
2025 Q4	$175K	Hold	950	–	–	0.06%	268
2025 Q3	$146K	Hold	950	–	–	0.05%	271
2025 Q2	$134K	Sell	950 -12	-1%	-$1.68K	0.05%	243
2025 Q1	$142K	Hold	962	–	–	0.06%	233
2024 Q4	$126K	Buy	962 +48	+5%	+$6.72K	0.06%	252
2024 Q3	$143K	Buy	914 +58	+7%	+$9.36K	0.07%	242
2024 Q2	$133K	Buy	856 +232	+37%	+$34.9K	0.07%	234
2024 Q1	$86K	Hold	624	–	–	0.05%	264
2023 Q4	$82K	Sell	624 -40	-6%	-$5.2K	0.06%	244
2023 Q3	$91K	Buy	664 +301	+83%	+$41.1K	0.07%	226
2023 Q2	$52K	Buy	363 +6	+2%	+$883	0.04%	292
2023 Q1	$50K	Hold	357	–	–	0.04%	276
2022 Q4	$48K	Buy	357 +100	+39%	+$12.5K	0.04%	274
2022 Q3	$28K	Buy	257 +145	+129%	+$18.4K	0.03%	331
2022 Q2	$15K	Hold	112	–	–	0.01%	408
2022 Q1	$15K	Buy	+112	New	+$13.4K	0.01%	421

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hazlett, Burt & Watson's AZN Position: Q2 2026 in Review

Hazlett, Burt & Watson increased its AstraZeneca (AZN) stake by 2.6% in Q2 2026, buying an estimated $5.27K and bringing the position to 1,107 shares worth $209K. The position accounts for 0.06% of the portfolio, ranked #259.

Hazlett, Burt & Watson first reported a position in AZN in Q1 2022 and has held it in 18 quarters since. The position peaked at $212K in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Hazlett, Burt & Watson held 1,107 shares of AstraZeneca worth $209K as of Q2 2026.
Hazlett, Burt & Watson bought 28 AstraZeneca shares in Q2 2026, an estimated $5.27K.
AstraZeneca made up 0.06% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #259 holding.
Hazlett, Burt & Watson first reported a position in AstraZeneca in Q1 2022 and has held it in 18 quarters since.
Hazlett, Burt & Watson's AstraZeneca position peaked at $212K in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.